ISSN: 1462-0324
Journal Home
Journal Guideline
Rheumatology Q1 Unclaimed
Rheumatology is a journal indexed in SJR in Rheumatology and Pharmacology (medical) with an H index of 198. It has a price of 2500 €. It has an SJR impact factor of 1,721 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,721.
Rheumatology focuses its scope in these topics and keywords: rheumatoid, arthritis, patients, disease, systemic, study, sclerosis, activity, response, ankylosing, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
2500 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
1,721
SJR Impact factor198
H Index675
Total Docs (Last Year)2199
Total Docs (3 years)18790
Total Refs7802
Total Cites (3 years)1532
Citable Docs (3 years)3.44
Cites/Doc (2 years)27.84
Ref/DocOther journals with similar parameters
Annals of the Rheumatic Diseases Q1
Nature Reviews Rheumatology Q1
Lancet Rheumatology, The Q1
Arthritis and Rheumatology Q1
Osteoarthritis and Cartilage Q1
Compare this journals
Aims and Scope
Best articles by citations
Complement activation in patients with systemic lupus erythematosus without nephritis
View moreReply
View moreExpression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus
View moreAn updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases
View moreMeta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs
View moreMetabolomic profiling reveals serum L-pyroglutamic acid as a potential diagnostic biomarker for systemic lupus erythematosus
View moreMycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients
View moreAnakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial
View moreAntibodies to parvovirus B19 non-structural protein are associated with chronic but not acute arthritis following B19 infection
View moreComplement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus
View moreEmergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease
View moreHypothalamic-pituitary-mediated immunomodulation: arginine vasopressin is a neuroendocrine immune mediator
View moreThe impact of primary Sjogren's syndrome on female sexual function
View moreHealth-related quality of life in gout: a systematic review
View moreDifficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval
View moreThe relationship between hand paraesthesia and occupational factors: results from a population study
View moreEfficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial
View moreA strong heritability of psoriatic arthritis over four generations--the Reykjavik Psoriatic Arthritis Study
View moreBilateral gluteal abscesses as a unique manifestation of Fusobacterium septicaemia
View moreVaginal dryness in primary Sjogren's syndrome: a histopathological case-control study
View moreComment on: Vaginal dryness in primary Sjogren's syndrome: a histopathological case-control study
View moreCentral role of mitochondria and p53 in Fas-mediated apoptosis of rheumatoid synovial fibroblasts
View moreGonococcal endocarditis in a patient with systemic lupus erythematosus
View moreA comparative quantitative morphometric study of cell apoptosis in synovial membranes in psoriatic, reactive and rheumatoid arthritis.
View more
Comments